IRobot and Acrivon Stock See Action From Activist Investors

These disclosures are from 13Ds filed with the Securities and Exchange Commission. 13Ds are filed within 10 days of an entity’s attaining more than 5% in any class of a company’s securities. Subsequent changes in holdings or intentions must be reported in amended filings. This material is from Nov. 24 through Nov. 30, 2022. Source: VerityData

Original Filings

Acrivon Therapeutics


(ACRV)

RA Capital revealed a fresh stake of 4,813,442 shares in the clinical-stage pharmaceutical firm, including 2,934 shares underlying options. RA Capital purchased 3,389,500 shares at $12.50 each through Acrivon’s November initial public offering. RA Capital gained another 1,421,008 Acrivon shares through the conversion of pre-IPO convertible preferred securities immediately after the offering closed on Nov. 17. RA Capital now owns a 23.1% stake in Acrivon.